Proteomic analysis identifies distinct GSRCC subtypes with divergent clinical outcomes. (IMAGE)
Caption
(A) Unsupervised clustering of 112 GSRCC cases identified key proteins with significant differences between tumors and NATs, focusing on the top 100 proteins with a FC > 1.5 and P value < 0.05. (B) Principal component analysis (PCA) visualizes the distribution of the identified subtypes, alongside HER2, EBV, and MSI status. (C) The Cox proportional hazards regression model was used to evaluate the impact of the newly identified subtypes and clinical factors on patient prognosis, calculating the hazard ratio (HR). (D) The associations between the four proteomic subtypes and overall survival in 112 GSRCC patients were assessed using the log-rank test, with Kaplan-Meier plots illustrating overall survival differences across subtypes. (E) Kaplan-Meier survival analysis stratified by TNM stage was further evaluated by overall survival variations among GSRCC subtypes. (F) Gene Set Enrichment Analysis (GSEA) identified significantly enriched biological pathways across GSRCC subtypes, with normalized scores highlighting key functional processes (adjusted P value < 0.05). GSRCC, gastric signet ring cell carcinoma; NATs, normal adjacent tissues; EBV, Epstein-Barr virus; HER2, human epidermal growth factor receptor 2; MSI, microsatellite instability.
Credit
Zhiyuan Jin, Li Yuan, Yubo Ma, Zu Ye, Zhao Zhang, Yi Wang, Can Hu, Jinyun Dong, Xinuo Zhang, Zhiyuan Xu, Yian Du, Xiaoqing Guan, Guangzhao Pan, Sichao Tian, Juan Li, Ruiwen Zhang, Jiangjiang Qin, Xiangdong Cheng
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND